Skip to contentI
Integra Lifesciences Holdings Corp
I
IARTIntegra Lifesciences Holdings Corp Q3 2020 · 10-Q
Revenue$370.23M$370.23M−2.3% vs Q3 2019 Net Income$32.34M$32.34MN/M vs Q3 2019 EPS Diluted$0.38$0.38N/M vs Q3 2019 Gross Profit$235,421,000−0.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR
Operating Cash Flowderived$69,639,000+8.4% Free Cash Flowderived$62,912,000+24.2% Margins · derivedGross margin63.6%+1.2 pt vs Q3 2019
Operating margin15.5%+21.0 pt vs Q3 2019
Net margin8.7%+16.0 pt vs Q3 2019
ended Sep 30, 2020 · filed Oct 29, 2020 · 29 d after period end